A combination of all-trans retinoic acid (ATRA) and arsenic trioxide resulted in outcomes “at least not inferior” to those achieved when ATRA was used in combination with idarubicin chemotherapy in newly diagnosed patients with non–high-risk, acute promyelocytic leukemia.
ARRY-520, a novel selective kinesin spindle protein (KSP) inhibitor showed promising clinical activity both alone and combined with low-dose dexamethasone in a phase II clinical trial in patients with relapsed and refractory multiple myeloma.
The combination of rituximab and the novel immunotherapy pidilizumab (CT-011) is both active and well tolerated in follicular lymphoma patients according to results of a phase II trial presented at ASH.
Preliminary findings presented at ASH suggest a “favorable emerging clinical profile” for once weekly administration of MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Updated findings from the pivotal phase II PACE trial show sustained benefit of the investigational BCR-ABL tyrosine kinase inhibitor ponatinib in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T-cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.
The targeted agent ibrutinib has shown a high response rate in both treatment-naive and previously treated, relapsed, refractory chronic lymphocytic leukemia (CLL) patients older than 65.
Today we speak with Steven T. Rosen, MD, about a couple of the projects he and his group are working on, repurposing old drugs for the treatment of multiple myeloma, that will be presented this year at ASH.
Data from an on-going early stage phase I/II trial of daratumumab in multiple myeloma continues to show promising activity. The dose-escalation study has shown that higher doses of daratumumab alone can reduce both bone marrow plasma cells as well as paraprotein.
Final results of a cohort from a phase II monotherapy trial of quizartinib in acute myeloid leukemia patients showed that more than half of patients 60 years of age and older who harbored an internal tandem duplication in the FMS-like tyrosine kinase 3 had a composite complete remission.